Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
The role of gut dysbiosis in shaping immunotherapy responses is well-recognized, yet its effect on the therapeutic efficacy of chemotherapy and immunotherapy combinations remains poorly understood. We analyzed gut microbiota in non-small cell lung cancer (NSCLC) patients treated with chemo-immunotherapy, comparing responders and non-responders using 16S rRNA sequencing. Responders showed higher microbial richness and abundance of specific genera like Faecalibacterium and Subdoligranulum, and the phylum Firmicutes. Support vector machine (SVM), a machine learning model based on microbial composition, predicted treatment efficacy with the area under the curve (AUC) values of 0.763 for genera and 0.855 for species. Metagenomic analysis revealed significant differences in metabolic pathways, with responders exhibiting higher short-chain fatty acids (SCFAs) production. Fecal microbiota transplantation (FMT) and SCFAs supplementation in mouse models enhanced treatment efficacy by promoting effector T cell activity in tumors. Our study suggests that gut microbiota, through SCFAs production, regulates chemo-immunotherapy efficacy, offering new strategies to improve NSCLC treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They can enhance PD‑1 blockade when administered orally (drinking water or gavage) at physiologically relevant concentrations.148–150”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [148]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016) · Cell · doi:10.1016/j.cell.2016.05.041 · Cited by 7,070
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Parada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J. M., Faber, K. N., & Hermoso, M. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00277 · Cited by 3,820
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Gut microbiome and health: mechanistic insights
de Vos, W. M., Tilg, H., Van Hul, M., & Cani, P. D. (2022) · Gut · doi:10.1136/gutjnl-2021-326789 · Cited by 2,388 · cited 2×
“F Linear discriminant analysis effect size (LEfSe) analysis, with a Linear Discriminant Analysis (LDA) threshold of 4,identi fi eskeymicrobiotataxaenrichedineachgroup,visualizedascolorednodes.”
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198 · cited 10×
“In the last decade, the emergence of immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) or its ligand (PD-L1) has led to signi fi cantly prolonged survival bene fi ts for NSCLC patients 1 – 3 .”
InfluentialRECIST 1.1—Update and clarification: From the RECIST committee
Schwartz, L. H., Litière, S., de Vries, E., Ford, R., Gwyther, S., Mandrekar, S., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.081 · Cited by 1,906
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · cited 1×
“Furthermore, successful fecal microbial transplantation (FMT) can alter the gut microbiota pro fi le and reverse the resistance to ICIs in patients with melanoma 3,8,13,14 .”
Research works printed but not linked: 1
- Mann, P. C.. International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Standardized terminology of pathological lesions in rats and mice [Translated into Chinese]. China Agricultural Press (2019).
Cited by
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Gut microbiome metabolites in lung cancer: The emerging importance of short-chain fatty acids
Bishoyi, A. K., Al-Hasnaawei, S., Salem, K. H., Ganesan, S., Shankhyan, A., Nanda, A., Sinha, A., Ray, S., Nathiya, D., & Hammady, F. J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115821 · Cited by 13
Harnessing the Gut Microbiota to Improve Cancer Immunotherapy: Focus on Lung Cancer
Park, U., Heo, J.-Y., Chun, S.-M., Lee, J.-C., Lee, S.-H., & Lee, S.-W. (2026) · Immune Network · doi:10.4110/in.2026.26.e7 · Cited by 11
“Metagenomic pathway analyses consistently revealed glycolysis, carbohydrate metabolism and SCFA biosynthesis pathways in responders (78,82).”
InfluentialEngineering microbial metabolites to modulate tumor immunity and advance cancer immunotherapy
Chigozie, V. U., & Esimone, C. O. (2026) · Discover Immunity. · doi:10.1007/s44368-026-00019-w · Cited by 11
“…inhibitors, whereas elevated polyamine concentrations in certain colorectal and breast tumor microenvironments can correlate with impaired antigen presentation and increased myeloid suppression, suggesting a narrow therapeutic window that must account for tumor metabolic phenotype [84, 152, 153].”
Liu, Y., Wang, S., Xiang, X., Du, Y., Xue, Q., Niu, Y., Peng, W., Ye, L., & Zhou, Q. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.126977 · Cited by 7
“BEVs Tumor burden reduction 2025 [141] Gut PD-1/PD-L1 inhibitors Hominenteromicrobium YB328 Prolonged PFS 2025 [178] Gut Chemo-immunotherapy combinations”
Influential
Metadata
- Authors
- Yang, Y., Ye, M., Song, Y., Xing, W., Zhao, X., Li, Y., Shen, J., Zhou, J., Arikawa, K., Wu, S., Song, Y., & Xu, N.
- Affiliations
- Fudan University (CN)
- Shanghai Medical College of Fudan University (CN)
- John H. Stroger, Jr. Hospital of Cook County (US)
- Corresponding author
- Song, Yijun
- Wu, Shengdi
- Song, Yuanlin
- Xu, Nuo
- ORCID
- Venue
- npj Biofilms and Microbiomes
- Published
- 2025-07-28
- Volume
- 11
- Issue
- 1
- Pages
- 146-146
- ISSN
- 2055-5008 (ISSN-L)
- PMC
- PMC12304354
- OpenAlex
- W4412701897
- Cited by
- 36
- References
- 38
- Citations by year
- 2026: 29 · 2025: 7
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- npj Biofilms and Microbiomes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Key R&D Plan (2020YFC2003700)
- Shanghai Municipal Science and Technology Major Project (ZD2021CY001)
- Science and Technology Commission of Shanghai Municipality (20Z11901000, 20DZ2261200, 20XD1401200, 22Y11900800)
- Clinical Research Plan of SHDC (SHDC2020CR5010-002)
- Shanghai Municipal Key Clinical Specialty (shslczdzk02201)
- Shanghai Municipal Health Commission and Shanghai Municipal Administrator of Traditional Chinese Medicine (ZY(2021-2023)-0207-01)
- National Natural Science Foundation of China (81401877, 82130001, and 82272243)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- gut microbiota, short-chain fatty acids, non-small cell lung cancer, chemoimmunotherapy, treatment response prediction, gut dysbiosis, Faecalibacterium, Subdoligranulum, Firmicutes, effector T cells, fecal microbiota transplantation, microbial biomarkers
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Aged, Animals, Antineoplastic Agents, Bacteria, Carcinoma, Non-Small-Cell Lung, Fatty Acids, Volatile, Female, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, RNA, Ribosomal, 16S, Treatment Outcome, Mice, Metagenomics, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC. https://app.cochat.ai/papers/10.1038/s41522-025-00785-9
- The paper
- Yang, Y., Ye, M., Song, Y., Xing, W., Zhao, X., Li, Y., Shen, J., Zhou, J., Arikawa, K., Wu, S., Song, Y., & Xu, N. (2025). Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC. npj Biofilms and Microbiomes. https://doi.org/10.1038/s41522-025-00785-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.